On August 21, 2026, Science News published a detailed look at the boom in low-intensity shock wave therapy for erectile dysfunction, and the picture it paints is a textbook case of a treatment market outrunning its evidence base. Men are increasingly skipping Viagra prescriptions in favour of clinics offering low-energy sound waves applied directly to the penis — a treatment that is not FDA-approved, that leading physician groups decline to endorse outside clinical trials, and that a lot of people are nonetheless paying real money for.

Why It Matters

Male sexual health has been the fastest-mainstreaming segment in this industry, powered by telehealth platforms that made a Viagra prescription a two-minute phone interaction. Shock wave therapy is what the next layer looks like: a cash-pay, in-person, device-mediated procedure sold on the promise of fixing the underlying tissue rather than renting an erection. That is a genuinely attractive pitch, and it is being made largely outside the specialty that owns the condition. For operators, the 25-percent-urologist figure is the number to sit with. A treatment category where three in four providers are outside the relevant specialty is one regulatory action or malpractice cluster away from a very different news cycle — and a separate Urology Times report notes that clinics frequently advertise radial wave therapy, a distinct modality with no proven ED utility, under the shockwave banner. That conflation is the real consumer-protection exposure. For the broader sex tech market, this is a useful calibration point on the "restorative therapy" wave now sweeping men's health, which also includes PRP injections (the so-called P-Shot) that SMSNA and the European Association of Urology both consider experimental. Devices promising tissue regeneration rather than symptom management command premium pricing and repeat visits, which is exactly the revenue model investors like. The honest read from the clinical literature is that low-intensity shockwave sits at "maybe helps some men with mild vasculogenic ED, low certainty" — a real signal, not a nothing, but nowhere near what the marketing implies. Anyone doing diligence in this segment should be asking which modality a clinic actually operates, and who is operating it.

The mechanism is at least plausible. Shock wave therapy via high-energy sound waves has been used for decades to shatter kidney stones; in 2010, doctors ran a trial of low-intensity waves in 20 middle-aged men with ED and found that six months out, half had improved enough for penetrative sex without Viagra-type drugs. Unlike lithotripsy, "the goal is not to destroy anything," urological surgeon James Weinberger of Beverly Hills told Science News, but to promote healing. In practice a clinician runs a chunky wandlike device over several areas of the penis for 15 to 20 minutes; it makes a snapping sound but shouldn't hurt. "The energy creates microscopic mechanical stresses at the cellular level," says urologist Taylor Kohn of Baylor College of Medicine. "Rather than compensating for the problem the way a pill does, the theoretical goal is to restore the tissue itself." Patients typically undergo six to 12 sessions that may run several hundred dollars each.

The demand is not in question. An analysis of 2021 survey data found 24.2 percent of responding US men experienced symptoms consistent with ED, rising to 52.2 percent among those 75 and up. The evidence is where it gets thin. Cochrane Library researchers analysing 21 studies found the technique might have a small effect on erectile function in the first few months with possible longer-term benefit, but variability across studies undercut the reviewers' confidence — a 2025 Cochrane review of those trials put the short-term gain at about 3.89 IIEF-EF points versus sham (95% CI, 2.89–4.89) while rating the evidence low-certainty. A 2026 report in Sexual Medicine Reviews found shock wave studies tended to be small and to vary in session count, making comparison difficult. Notably, none reported evidence of harm; most side effects in trials are skin reactions to the coupling gel.

The sharper concern is who is holding the wand. Of the 152 clinics across eight major US metro areas that Weinberger and colleagues identified offering the therapy — a count he says "certainly undercounts what exists today" — only 25 percent of providers were urologists. The rest included primary care physicians, other reproductive health specialists, plastic surgeons, dermatologists and even chiropractors. That matters, Weinberger argues, because proper ED treatment involves conversations about hormones and medications that a stand-alone ED clinic may never have. Kohn reserves the treatment for men who still respond to Viagra-type drugs: "If you're no longer responding to oral medications, or having no erections at all, it's kind of a waste of time." Both the American Urological Association and the Sexual Medicine Society of North America say the evidence isn't strong enough to warrant use outside clinical trials.

Sources

Update — 2026-08-25

{Initial entry — story first created.}